Floatz logo

Golidocitinib

Cutaneous T Cell Lymphoma

Institute of Hematology & Blood Diseases Hospital, ChinaSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

16 Active assets in the Cutaneous T Cell Lymphoma cohort.

Asset / SponsorPhaseRating
MOGAMULIZUMAB
University of Michigan Rogel Cancer Center
Phase 4BB
VITPSO
Columbia University
Phase 4BB
Epirubicin
Seda S. Tolu
Phase 2BB
4,5,7,4',5',7'-HEXAHYDROXY-2,2'-DIMETHYLNAPHTHODIANTHRONE
Soligenix
Phase 3BB
Pembrolizumab
Seda S. Tolu
Phase 2BB

View all 25 →

Same molecule, other indications

Golidocitinib is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
68 / 100
View asset →
peripheral T-cell lymphoma, not otherwise specifiedDormant
B
Indicative ·
63 / 100
View asset →
extranodal nasal NK/T cell lymphomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →